Journal of Diabetes & Clinical Practice
Open Access

Diabetes is a chronic condition that requires long-term management to control blood sugar levels and prevent complications. While lifestyle modifications, such as diet and exercise, are fundamental in managing diabetes, pharmacological interventions are often necessary to achieve optimal glycemic control. Traditionally, diabetes treatment has involved the use of a single class of medications, such as insulin or oral hypoglycemic agents. However, the growing complexity of managing diabetes and the increasing burden of diabetes-related complications have led to the exploration of combination therapies as a more effective approach. Combination therapies involve the use of two or more drugs that work through different mechanisms to improve blood sugar control and reduce the risk of complications such as cardiovascular disease, nephropathy, retinopathy, and neuropathy. This article explores the efficacy of combination therapies in controlling blood sugar levels and preventing diabetes-related complications, with a focus on the mechanisms behind their effectiveness and the potential benefits they offer over monotherapy [1].

The Rationale for Combination Therapy

The rationale behind combination therapy for diabetes management stems from the understanding that diabetes is a multifactorial disease that involves several pathophysiological processes, including insulin resistance, impaired insulin secretion, and increased hepatic glucose production. Monotherapy often targets only one of these mechanisms, which may not be sufficient to achieve optimal blood sugar control in all patients. Combination therapies, on the other hand, can simultaneously address multiple aspects of the disease, leading to more comprehensive glycemic control [2]. In addition to improving glycemic control, combination therapies have the potential to reduce the risk of long-term complications associated with diabetes. Diabetes-related complications, such as cardiovascular disease, diabetic retinopathy, and nephropathy, are a major cause of morbidity and mortality in diabetic patients. Many of these complications are driven by hyperglycemia, but other factors such as inflammation, oxidative stress, and endothelial dysfunction also play critical roles. By targeting multiple pathways simultaneously, combination therapies may provide greater protection against these complications compared to single-drug treatments.

Commonly Used Combination Therapies

Several combinations of diabetes medications are currently used in clinical practice, each with its own specific benefits and mechanisms of action. Some of the most common combination therapies include

Metformin and DPP-4 Inhibitors: Metformin is often considered the first-line therapy for type 2 diabetes due to its ability to reduce hepatic glucose production and improve insulin sensitivity. When combined with dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase the levels of incretin hormones (such as GLP-1), the combination enhances insulin secretion in response to meals and improves postprandial blood sugar control. This combination is well-tolerated and effective in controlling blood sugar with a low risk of hypoglycemia [3].

Metformin and SGLT-2 Inhibitors: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors work by inhibiting glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and lower blood sugar levels. Combining SGLT-2 inhibitors with metformin can provide complementary mechanisms of action. Metformin improves insulin sensitivity, while SGLT-2 inhibitors reduce blood sugar through a glucose-lowering effect in the kidneys. This combination has been shown to improve glycemic control, promote weight loss, and reduce the risk of cardiovascular events [4].

GLP-1 Receptor Agonists and Insulin: GLP-1 receptor agonists, such as liraglutide and semaglutide, mimic the effects of the natural incretin hormone GLP-1, enhancing insulin secretion and inhibiting glucagon release. When combined with insulin, GLP-1 receptor agonists can reduce the insulin dose required to control blood sugar levels and improve glycemic control without increasing the risk of hypoglycemia. This combination has also been shown to promote weight loss, which is particularly beneficial in patients with type 2 diabetes who are overweight or obese.

Insulin and Sulfonylureas: Sulfonylureas, such as glimepiride and glipizide, stimulate the pancreas to release more insulin. When combined with insulin, sulfonylureas can help achieve more consistent blood sugar control by supplementing the insulin dose and improving the body’s response to insulin. This combination is often used in patients with advanced type 2 diabetes who require insulin therapy but have not achieved adequate glycemic control with insulin alone [5].

Metformin and Thiazolidinediones (TZDs): Thiazolidinediones, such as pioglitazone, work by improving insulin sensitivity in peripheral tissues, including muscle and fat. When combined with metformin, TZDs can enhance the body’s ability to utilize glucose and improve blood sugar control. This combination is particularly useful for patients with significant insulin resistance, although the potential for weight gain and fluid retention with TZDs may limit their use in some individuals [6].

Efficacy of Combination Therapies

Combination therapies have demonstrated superior efficacy in controlling blood sugar levels compared to monotherapy. One of the key advantages of combination therapy is that it can provide more comprehensive control of both fasting and postprandial blood glucose levels. For example, while metformin primarily reduces fasting blood glucose levels, DPP-4 inhibitors and GLP-1 receptor agonists are particularly effective in controlling postprandial glucose spikes. By targeting both aspects of glucose regulation, combination therapies can achieve better overall glycemic control. Moreover, combination therapies can lead to more significant reductions in HbA1c, the primary marker for long-term blood glucose control. Studies have shown that combination therapies can achieve reductions in HbA1c of up to 1.5% or more, which is often sufficient to meet treatment goals. In contrast, monotherapy typically leads to smaller reductions in HbA1c, particularly in patients with more advanced diabetes or insulin resistance [7]. Another advantage of combination therapies is the potential for weight loss. Medications such as GLP-1 receptor agonists and SGLT-2 inhibitors have been shown to promote weight loss, which can be beneficial for many patients with type 2 diabetes who are overweight or obese. Weight loss not only improves blood sugar control but also reduces the risk of cardiovascular disease and other diabetes-related complications.

Prevention of Diabetes-Related Complications

In addition to improving blood sugar control, combination therapies have the potential to prevent or delay the onset of diabetes-related complications [8]. Cardiovascular disease is one of the leading causes of death in individuals with diabetes, and controlling blood sugar alone may not be sufficient to reduce the risk of heart attacks, strokes, and other cardiovascular events. However, certain combination therapies, such as metformin with SGLT-2 inhibitors, have shown promise in reducing cardiovascular risk by improving blood pressure, lipid profiles, and endothelial function. SGLT-2 inhibitors, in particular, have been shown to reduce the incidence of heart failure and chronic kidney disease, both of which are common complications of diabetes. Combination therapies that target multiple pathways involved in inflammation, oxidative stress, and endothelial dysfunction may also help protect against diabetic nephropathy, retinopathy, and neuropathy. For example, GLP-1 receptor agonists have been shown to have anti-inflammatory effects and may reduce the progression of diabetic nephropathy, while SGLT-2 inhibitors offer renal protection by reducing glomerular hyperfiltration and inflammation [9].

Safety Considerations and Challenges

Despite the benefits of combination therapies, there are several safety considerations that must be taken into account. The risk of hypoglycemia is a major concern when using insulin or sulfonylureas in combination with other glucose-lowering agents. Careful monitoring of blood glucose levels and appropriate dose adjustments are necessary to minimize the risk of hypoglycemic episodes. Additionally, some combination therapies, such as those involving thiazolidinediones, may be associated with side effects such as weight gain, fluid retention, and an increased risk of fractures. Patient adherence to combination therapies can also be a challenge, as complex regimens involving multiple medications may be difficult to manage. The use of fixed-dose combination pills, which combine two or more medications into a single tablet, can help simplify treatment regimens and improve patient adherence. However, it is essential to personalize treatment plans based on individual patient needs, preferences, and tolerability [10].

Conclusion

Combination therapies represent a promising approach to managing diabetes by targeting multiple pathways involved in the disease process. These therapies offer improved glycemic control, greater reductions in HbA1c, and the potential for better outcomes in terms of preventing diabetes-related complications such as cardiovascular disease, nephropathy, and neuropathy. While combination therapies are generally more effective than monotherapy, they must be carefully selected and monitored to minimize the risk of adverse effects, such as hypoglycemia and weight gain. By tailoring treatment regimens to individual patients and utilizing fixed-dose combination pills, healthcare providers can optimize diabetes management and improve the quality of life for individuals with diabetes.

1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, et al. (2022) IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183

            Google Scholar, Crossref

2. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, et al. (2005) comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80: 45-53.

Indexed at, Google Scholar, Crossref

3. Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, et al. (2008) Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 3: 2398-2403

Indexed at, Google Scholar, Crossref

4. Centorrino F, Hernan MA, Drago-Ferrante G, Rendall M (2009) The economic burden of comorbid psychiatric and endocrine disorders: a systematic review and meta-analysis. Psychiatr Serv 60: 693-702.

Google Scholar

5. Balhara YP (2011) Diabetes and psychiatric disorders. Indian J Endocrinology and metabolism 15: 274-283.

Indexed at, Google Scholar, Crossref

6. Wu Y, Ding Y, Tanaka Y, Zhang W (2014) Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci 11: 1185.

Indexed at, Google Scholar

7. Gilani SR, Feizabad AK (2019) The effects of aerobic exercise training on mental health and self-esteem of type 2 diabetes mellitus patients. Health psychology research 7: 6576.

Indexed at, Google Scholar, Crossref

8. Ogurtsova K, Guariguata L, Barengo NC, Sacre JW, Karuranga S, et al. (2022) IDF diabetes Atlas: global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract 183.

                Indexed at, Google Scholar, Crossref

9. Coodin S (2001) Body mass index in persons with schizophrenia. Can J Psychiatr 46: 549-555.

Indexed at, Google Scholar, Crossref

10. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, et al. (2017) Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatric Dis Treat 13: 2231-2241.

Indexed at, Google Scholar, Crossref